Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 1.42
- Piotroski Score 5.00
- Grade Overweight
- Symbol (AMGN)
- Company Amgen Inc.
- Price $316.00
- Changes Percentage (-0.37%)
- Change -$1.17
- Day Low $314.82
- Day High $319.21
- Year High $346.85
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
- Last Earnings 10/25/2024
- Ex-Dividend for 5/16 Dividend 11/18/2024
- Dividend Payable 12/09/2024
- Today N/A
- Next Earnings (Estimated) 10/30/2024
- Fiscal Year End N/A
- Average Stock Price Target $303.00
- High Stock Price Target $380.00
- Low Stock Price Target $182.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $7.00
- Trailing P/E Ratio 43.57
- Forward P/E Ratio 43.57
- P/E Growth 43.57
- Net Income $6.72 B
Income Statement
Quarterly
Annual
Latest News of AMGN
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Amgen Inc. (AMGN): A Buzzing AI Health Stock to Add to Your Portfolio
The article discusses the impact of AI in healthcare, with a focus on Amgen Inc. as one of the top buzzing AI health stocks. AI is projected to drive transformative growth in healthcare, enhancing dia...
By Yahoo! Finance | 3 weeks ago -
Amgen (AMGN) Rose Owing To The Announcement Of Promising Data For Its Novel Medication
PGIM Jennison Health Sciences Fund's Q2 2024 investor letter discussed stock performance, highlighting Amgen Inc. (NASDAQ:AMGN). The fund noted Amgen's one-month return and market capitalization. They...
By Yahoo! Finance | 3 weeks ago -
Amgen Inc. (AMGN): Hedge Fund Interest and Strong Pipeline Support Moderate Buy Rating
A recent article ranks Amgen Inc. (NASDAQ:AMGN) as the 9th best healthcare stock to buy according to hedge funds. The healthcare sector is growing, with increasing healthcare spending and advancements...
By Yahoo! Finance | 4 weeks ago
